Savara is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara’s pipeline comprises: Molgradex, a Phase 3 stage inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF; AeroVanc, a Phase 3 ready inhaled vancomycin, and Aironite, a Phase 2 stage inhaled sodium nitrite.
Molgradex for PAP
Molgradex is the first treatment being developed for inhalation of GM-CSF for the treatment of patients suffering from a rare respiratory disease called pulmonary alveolar proteinosis (PAP).
AeroVanc for CF
AeroVanc is the first inhaled antibiotic being developed to address the growing problem of chronic methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people with cystic fibrosis (CF).
Aironite for HFpEF
Aironite is an inhaled formulation of sodium nitrite that is being developed for the treatment of heart failure patients with preserved ejection fraction (HFpEF).